TABLE 6.

Results of pairwise meta-analyses for NFDs.

Comparative medication	Reference medication	Number of studies	Pairwise meta-analyses
			Number of control	Number of patients	MD/OR/RR	95% CI	I2	P
XNJ	Placebo	13	356	347	−3.78	[−4.75, −2.81]	54	0.00001
NST	Placebo	13	100	100	8.15	[10.11, 49.10]	95	0.0005
Chuanxiong	Placebo	3	80	81	−3.11	[−5.22, −1.00]	0	0.0039
Safflower yellow	Placebo	7	368	394	3.11	[2.06, 4.68]	0	0.00001
Rhubarb	Placebo	12	210	210	−3.36	[−6.10, −0.62]	89	0.00001
Puerarin	Placebo	16	659	699	−3.69	[−4.67, −2.71]	70	0.00001
Albumin	Placebo	4	804	807	1.04	[0.85, 1.27]	0	0.65
Salvianolic acids	Placebo	12	235	235	−8.65	[−11.10, −6.20]	31	0.001
Pntsp	Placebo	20	1464	1435	−3.36	[−4.20, −2.53]	74	0.0001
Nimodipine	Placebo	8	677	806	0.54	[0.50, 0.78]	NA	0.0001
HUK	Placebo	9	338	338	1.30	[1.21, 1.41]	0	0.00001
DZSM	Placebo	5	341	340	−2.81	[−4.17, −1.44]	85.9	0.1
Mailuoning	Placebo	15	736	755	0.31	[0.23, 0.42]	0	0.001
TNK	Placebo	4	656	671	1.56	[1.0, 2.43]	0	0.05
MLC601	Placebo	2	275	520	0.27	[−0.02, 0.55]	66	0.06

CI, confidence interval; MD, mean difference; OR, risk ratio; I², heterogeneity, NST, NaoShuanTong capsule; XNJ, Xingnaojing capsule; Pntsp, Panax notoginseng Saponin; TQHX, Tongqiao Huoxue decoction; TNK, tenecteplase.